Objective-Prostacyclin and thromboxane mediate opposing cardiovascular effects through their receptors, the prostacyclin receptor (IP) and thromboxane receptor (TP). Individuals heterozygous for an IP variant, IP R212C , displayed exaggerated loss of platelet IP responsiveness and accelerated cardiovascular disease. We examined association of IP R212C into homo-and heterodimeric receptor complexes and the impact on prostacyclin and thromboxane biology. Methods and Results-Dimerization of the IP, IP R212C , and TP␣ was examined by bioluminesence resonance energy transfer in transfected HEK293 cells. We observed an equal propensity for formation of IPIP homodimers and IPTP␣ heterodimers. Compared with the IP alone, IP R212C displayed reduced cAMP generation and increased endoplasmic reticulum localization but underwent normal homo-and heterodimerization. When the IP R212C and IP were coexpressed, a dominant negative action of the variant was evident with enhanced wild-type IP localization to the endoplasmic reticulum and reduced agonist-dependent signaling. Further, the TP␣ activation response, which was shifted from inositol phosphate to cAMP generation following IPTP␣ heterodimerization, was normalized when the TP␣ instead dimerized with IP R212C .
T he prostanoids are formed following conversion of arachidonic acid by cyclooxygenase (COX)-1 and COX-2. 1 Thromboxane A 2 (TxA 2 ), which is derived predominantly from platelet COX-1, is a well-established contributor to cardiovascular disease (CVD). 2 Indeed, the cardioprotective effects of aspirin result from irreversible inhibition of platelet COX-1-derived TxA 2 , 3 reflecting the central role of TxA 2 as a platelet agonist in CVD. A second major vascular prostanoid, prostacyclin (PGI 2 ), which is derived predominantly from vascular endothelial COX-2, 4 is an established antithrombotic, antiproliferative vasodilator. 2 PGI 2 's cardiovascular effects (platelet inhibition, vasodilation, and decreased proliferation) directly oppose those of TxA 2 . 4 Indeed, depression of PGI 2 generation, with unrestricted biosynthesis of TxA 2 via COX-1, provides a mechanistic explanation for the cardiovascular hazard associated with selective COX-2 inhibitors. 4 Distinct G protein-coupled receptor (GPCR) signaling pathways drive the opposing effects of PGI 2 and TxA 2 . 1,2 PGI 2 , via its receptor (the IP), elevates cellular cAMP, whereas activation of the TxA 2 receptor (the TP) elevates inositol phosphates (InsP) and intracellular calcium. We 5, 6 and others 7, 8 report that, similar to other GPCRs, 9 IP and TP associate to form homo-and heterodimers. Interestingly, heterodimerization with the IP facilitated coupling of the TP␣ to cAMP generation (an IP-like cellular response) 6 and rendered the TP sensitive to regulation by IP agonists. 5 Importantly, this occurred not only in transfected cells but also in vascular smooth muscle cells, which endogenously express IP and TP. Therefore, when IP and TP are present in the same cell, a common occurrence in cardiovascular tissues, cAMP can be generated via the PGI 2 -IPIP and TxA 2 -IPTP pathways. This signaling shift likely contributes to the limit placed by the IP on the deleterious cardiovascular effects of TP activation.
Genetic IP variants display altered expression, ligand binding, and function. 10 One variant, IP R212C , which occurs at low frequency (0.8% in white and Asian cohorts), displayed impaired signaling and was associated with accelerated CVD in 2 studies. 11, 12 Strikingly, all but one IP R212C carrier identified to date are heterozygous for the mutant. Platelets from IP R212C heterozygote individuals are functionally nonresponsive to a PGI 2 analog. 11 This contrasts with the gene dosage effect in mice heterozygous for IP deletion, in which the ex vivo platelet response to a PGI 2 analog, as well as accelerated thrombosis in vivo, fell midway between wildtype and IP null animals. 13 Taken together, these data suggest a dominant negative action of IP R212C on the wild-type receptor in heterozygous individuals. Whether and how IP R212C modifies wild-type IP function has not been examined. However, according to the current information regarding structural requirements for class A GPCRs dimerization, 14, 15 IP R212C should dimerize normally. Because IP is a dimeric partner for at least 2 GPCRs (itself, 7 to form IPIP homodimers, and the TP␣, to form IPTP␣ heterodimers 5, 6 ), this raises the intriguing possibility that the mutant may modify the function of an associated receptor in a homo-or heterodimeric assembly. The aim of this study was to examine the effect of IP R212C on its dimeric partners. We evaluated whether dimerization of IP R212C with the wild-type IP might account its dominant negative action and whether association of IP R212C with IP and/or TP may contribute to accelerated CVD in IP R212C carriers.
Methods
Detailed methods are provided as supplemental information, available online at http://atvb.ahajournals.org. Receptors were fused to renilla luciferase (rLuc) or yellow fluorescent protein (YFP) or tagged with hemagglutinin (HA) or Myc epitope tags. Receptor dimerization (by bioluminesence resonance energy transfer [BRET]), signaling (by quantifying cellular cAMP and InsP generation), and cellular localization (by immunofluorescent microscopy) were examined in HEK293 cells, 48 hours after transfection.
Results

Homodimerization of IP and TP␣ by BRET
IP homodimerization has been observed, previously, by Western blot analysis and coimmunoprecipitation. 6, 7 Because these are qualitative methods for indirect analysis of dimerization, we first confirmed and refined these studies using a quantitative methodology, BRET. 15 We chose the BRET 1 method, in which receptors are fused to either a donor (rLuc) or acceptor (YFP). 16 Transfer of energy, on addition of rLuc substrate, reflects the physical interaction of donor and acceptor to within 10 nm.
IP homodimerization was confirmed in HEK293 cells transfected with IPrLucϩIPYFP. In BRET saturation experiments, a constant amount of IPrLuc was combined with gradually increasing levels of IPYFP. Receptor expression was at low physiologically relevant levels (Ͻ50 fmol/mg protein by 3 H-iloprost binding to membranes prepared from transfected cells). The IPrLuc:IPYFP curve was saturable, indicating a specific interaction ( Figure 1A and 1B). Total YFP emission was measured, in separate samples, to quantify IPYFP expression ( Figure 1B ). The BRET 50 (the level of YFP fusion protein, as fold over basal, that produced 50% of the maximal signal) was 1.27Ϯ0.06 for IP homodimerization, consistent with high-affinity association. Lower nonsaturable BRET was observed when IPrLuc was combined with YFPfused DP 1 , a receptor for PGD 2 ( Figure 1A and 1C ), indicating no interaction. PGD 2 is a vasoactive prostaglandin that, similar to PGI 2 , mediates vasodilation and platelet inhibition via a Gs-coupled receptor, 17 making it an excellent and biologically relevant control. The absence of a IPϩDP 1 signal was not because of poor DP 1 YFP expression. In unrelated studies that used DP 1 YFP as an acceptor, a normal and saturable BRET signal was recorded (data not shown). Low nonsaturable BRET was also observed when IPrLuc was combined with empty YFP vector (data not shown).
We next performed competition analyses in which BRET was measured with or without unfused (ie, neither rLuc-nor YFP-fused) HA-tagged IP. Inclusion of HA-IP significantly reduced the IPrLuc:IPYFP BRET signal ( Figure 1D ). The apparently small absolute reduction in BRET likely reflects the array of possible assemblies that arise from the combination of 3 IP species (IPrLuc, IPYFP, and HA-IP). Thus, each monomer can interact with an identical or alternatively labeled monomer. However, it is only through interruption of the IPrLuc:IPYFP association that unfused HA-IP can alter the BRET signal, resulting in the apparently small reduction. The consistent and highly significant reduction in BRET by unfused IP strongly supports the saturation data and validates our BRET 1 system for measurement of receptor dimerization.
High-affinity TP␣ homodimerization was also readily evident by BRET saturation analysis (BRET 50 ϭ1.24Ϯ0.1, nϭ6; Figure 1E and 1F). Thus, similar to the IP, high-affinity association of the TP␣ to form homodimers was observed.
Heterodimerization of IP With TP␣ by BRET
We previously reported heterodimerization of the TP␣ with IP, with consequent changes in TP␣ signaling and regulation. 5, 6 Here, we confirmed IPTP␣ heterodimerization by BRET. IPrLuc:TP␣YFP BRET was saturable (BRET 50 ϭ 1.49Ϯ0.4, nϭ4; Figure 2A and 2B). Interestingly, despite the clear indication of IPTP␣ heterodimerization by BRET (and by coimmunoprecipitation 6 ), unfused HA-IP did not reduce the IPrLuc:TP␣YFP BRET signal. This was evident with either an excess (20ϫ) of HA-IP ( Figure 2C ) or with increasing HA-IP combined with a single midrange level of IPrLucϩIPYFP ( Figure 2D ). Similar results were obtained when unfused TP␣ was the competitor (data not shown). These data support the notion that IPTP␣ heterodimerization occurs in a manner that is distinct from the IPIP homodimers.
IP R212C Dimerization With IP or TP␣
Structural studies suggest that the dimerization of class A GPCRs is mediated through their transmembrane domains. 18, 19 However, the specific site(s) that direct IP dimerization is unknown. It was unclear, therefore, whether the IP R212C would display an altered propensity to dimerize. We examined dimerization of IP R212C with itself, with wild-type IP, or with TP␣. A specific and saturable interaction was evident in IP R212C rLuc:IP R212C YFP saturations (BRET 50 ϭ 1.13Ϯ0.08, nϭ3; Figure 3A and 3B). Similar results were obtained with IPrLucϩIP R212C YFP or IP R212C rLucϩIPYFP ( Figure 3A ). Apparent differences in the curves in Figure 3A most likely arise from differences in the efficiency of IP versus IP R212C fusion protein expression. IP R212C also reflect dimerized efficiently with the TP␣ ( Figure 3C ). Together, these data indicate no detectable impact of the mutation on IP R212C homo-or heterodimerization (supplemental Table I ).
Cellular Localization of IP and IP R212C
IP R212C is retained in the endoplasmic reticulum (ER), reducing its plasma membrane expression. 11 We considered whether, similar to other ER-retained mutant GPCRs, 20 IP R212C could promote ER retention of the wild-type IP. Myc-IP and HA-IP R212C were expressed, alone or in combination. Because of the equivalent affinity for IP to interact with another IP or with IP R212C (supplemental Table I ), we used IP R212C at a 2:1 excess, minimizing the amount of wild-type IP not associated with the variant. When transfected alone, Myc-IP was distributed diffusely in cytoplasm, ER, and plasma membrane ( Figure 4A and supplemental Figure IA and IB). This pattern is typical for transiently transfected GPCRs and was observed also in cells transfected with HA-DP 1 (Figure 4B ). Myc-IP was clearly observed in regions that were negative for the ER marker calnexin (supplemental Figure IA and IB; dotted lines) and was not modified by coexpression of HA-DP 1 , a noninteracting control ( Figure 4B ). As previously reported, 11 HA-IP R212C was concentrated in the ER ( Figure 4C ). When coexpressed with HA-IP R212C , Myc-IP distribution was markedly altered with intense localization of the wild-type receptor in focal calnexin-positive areas ( Figure 4C and supplemental Figure  IC) . These data provide qualitative support for the physical interaction of IP and IP R212C leading to ER retention of the wild-type receptor.
Effect of IP R212C on Wild-Type IP Function
Accelerated CVD in IP R212C heterozygote individuals was associated with an exaggerated loss of IP-dependent platelet cAMP generation to nonfunctional levels. 11 We considered, therefore, the impact of IP R212C on wild-type IP function. First, HEK293 cells were transfected individually, with HA-IP R212C or HA-IP and the response to a PGI 2 analog (cicaprost) examined. Significantly lower cAMP was generated via IP R212C compared with IP ( Figure 5A ), confirming the mutant's previously reported signaling deficiency. 11 The IP R212C response remained depressed when the variant was increased to 2ϫ ( Figure 5B ), 3ϫ ( Figure 5D , white bar), or 4ϫ (data not shown) in single transfectants. Thus, the maximal ability for IP R212C to signal was significantly below that of the wild-type receptor.
In cells cotransfected with HA-IP R212C ϩHA-IP (2:1), cAMP generation was significantly lower than the expected additive value calculated from parallel single transfections ( Figure 5C ). This impaired response was also observed when IP R212C was introduced at 2ϫ or 3ϫ the level of the coexpressed wild-type IP ( Figure 5D , hatched and striped columns). Indeed, across all single and cotransfection experiments that included IP R212C , cAMP levels were depressed by 50 to 70% compared with the wild-type IP alone ( Figure 5D ). Thus, IP R212C acted in a dominant fashion to "impose" its signaling deficiency on the wild-type receptor. We hypothesize that this occurs through interruption of IPIP homodimerization and/or formation of an IPIP R212C dimer.
IP R212C Does Not Facilitate TP␣-cAMP Signaling
When associated with the IP, activation of the TP␣ led to a robust cAMP response. 6 We posited this as a mechanism through which the IP can limit TP function. Given that IP R212C efficiently heterodimerizes with the TP␣, we considered the impact of IP R212C on TP␣ signaling. Coexpression of the wild-type IP (2ϫ) with TP␣ (1ϫ) facilitated a cAMP response to TP␣ activation ( Figure 6A ), as reported. 6 In contrast, the cAMP response to a TxA 2 analog, [1S-[1␤,2␣(Z),3␣(1E,3S*),4␣]]-7-[3-[3-hydroxy-4-(4Ј-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5Ј-heptenoic acid (IBOP), in IP R212C ϩTP␣ cotransfectants, was returned to levels similar to that observed in parallel singly TP␣-transfected cells ( Figure 6A ). These data demonstrate that, although its ability to heterodimerize with the TP␣ was intact, IP R212C did not recapitulate the impact of the wild-type IP on TP␣-cAMP signaling.
IP R212C Was Less Effective Than IP in Reducing TP␣-InsP Signaling
Finally, we examined how IP and IP R212C modified the ability of TP␣ to activate phospholipase C. When cotransfected with wild-type IP (2ϫ), the InsP response to TP␣ (1ϫ) activation was significantly reduced ( Figure 6B ). Taken together with the data in Figure 6A , it appears that, when heterodimerized with IP, TP␣ coupling was shifted from phospholipase C to adenylyl cyclase. In contrast, and concomitant with the absence of a TP␣-cAMP signal, IBOP-induced InsP generation was normalized in HA-IP R212C (2ϫ)ϩHA-TP␣ (1ϫ) cotransfectants ( Figure 6B ). This is consistent with the concept that the mutant was unable to shift TP signaling and instead allowed the InsP signal to dominate. Thus, the deficiency associated with the IP R212C extended beyond its own signaling pathway to impact its heterodimeric partner.
Discussion
Studies in mice and humans indicate the critical contribution made by PGI 2 -IP and TxA 2 -TP to cardiovascular function and disease. 1, 2 Similar to other GPCRs, the IP and TP form homo-and heterodimers that may be integral to their function and regulation. [5] [6] [7] [8] Of particular relevance to CVD, we reported how heterodimerization with the TP may contribute to the limit placed by the IP on TxA 2 function. 5, 6 Recent studies reveal a significant level of genetic variability in the human IP 21 with at least 1 variant, IP R212C , associated with accelerated CVD. 11 Because expression of IP R212C is almost exclusively heterozygous, 11 we considered it important to examine this variant in the context of coincident expression of wildtype IP, as well as TP. We reasoned that IP R212C could alter, through dimerization, the function of wild-type IP in heterozygote individuals. Furthermore, IP R212C may compete with the IP for heterodimerization with the TP. Either or both of these events may modify the cardiovascular response to PGI 2 and/or TxA 2 .
We confirmed the IP R212C signaling deficiency and report its normal capacity to homo-and heterodimerize. We describe a dominant negative action of IP R212C on wild-type IP function, which enhanced ER retention of the IP and reduced signaling in response to a PGI 2 analog. These observations provide a mechanistic basis for the exaggerated impact of IP R212C on the cAMP response to a PGI 2 analog in platelets from heterozygous individuals. 11 Further, the response to a TxA 2 analog, which was shifted from InsP to cAMP generation following IPTP␣ heterodimerization, was normalized when the TP␣ instead dimerized with IP R212C . Thus, a cellular mechanism through which the IP can limit TP function was minimized, likely contributing to accelerated CVD in IP R212C carriers.
Our study is the first to use BRET to examine prostanoid receptor dimerization. In BRET studies, it is critical to establish that energy transfer results from specific, nonrandom interactions between the rLuc-fused donor and YFPfused acceptor. Protein conformation and 3D structure can alter acceptor/donor orientation. Hence, the magnitude of the BRET signal does not fully reflect the amount of dimer or the affinity of the interactors. Consequently, it is insufficient to conclude protein interaction based on measurable BRET above background, and it is critical to demonstrate saturable BRET. 16, 22 We performed BRET saturations combining a fixed level of donor with gradually increasing acceptor. BRET was plotted against the molar ratio of transfected receptor-YFP to receptor-rLuc to assess saturability and reproducibility. In this analysis, saturation of the BRET signal indicates a specific interaction, but the slope of the curve, which is dependent on the actual cellular expression of receptor-YFP achieved, does not reflect affinity. Therefore, BRET was also plotted against total YFP emission (excited at 485 nm), expressed as fold over basal, as a measure of actual YFP-receptor expression. Saturation again indicates specificity, whereas the slope reflects affinity and may be quantified, in each dataset, as the BRET 50 .
A highly reproducible and saturable BRET signal was recorded in cells transfected with IPrLucϩIPYFP, consistent with a high-affinity homodimerization. Similar high-affinity interactions were evident for TP homodimerization and IPTP heterodimerization, with no significant difference in BRET 50 for these 3 interactions (supplemental Table I ). This is important when considering the likelihood of dimerization of native receptors. Indeed, although saturable BRET was observed in ␣A1-adrenoreceptorϩѨ-opioid receptor cotransfection studies, the markedly higher BRET 50 value for the heterodimer suggests that this interaction is unlikely to occur in vivo. 23 Our data support equal propensity for IP and TP homo-and heterodimerization providing for at least 3 native dimeric species (IPIP, TPTP, and IPTP). Concordantly, we observed cellular signaling consistent with formation of all 3 species in aortic smooth muscle cells, 6 supporting homo-and heterodimerization of the native receptors.
Fusion to energy donor or acceptor moieties is essential for BRET. Thus, we relied on a transfection system for our studies. This is a major limitation of BRET and raises concerns of artifactual interactions. We are confident that this is not the case for several reasons. First, receptor expression in BRET studies was at low physiological levels. Second, we examined extensively the saturation of BRET, and not the simple measurement of a BRET signal, as evidence of true dimerization. Finally, the lack of saturable BRET between IP and DP 1 considerably strengthens our confidence that BRET is not an artifact of receptor expression in nonnative cells. We recognize, however, the importance of confirming our BRET studies in native cells.
Currently, it is believed that the association of GPCRs occurs in the ER, from where correctly folded and dimerized receptors are transported to the Golgi. Indeed, dimer/oligmerization may be a necessary quality control step for ER/Golgi export. 9, 15 The factors and molecular pathways that regulate this process are largely unknown, but the concentration of individual receptors may be a contributing factor. As an example, augmented expression of the B2 receptor for bradykinin increased heterodimerization with the AT1 angiotensin II receptor with consequent elevation in angiotensin II responses. 24 We reported recently augmented TP expression following its activation, 25 a process that may contribute to elevated TP levels in animal models of CVD and in human disease. Our studies suggest that IP dimerization with the TP, and the consequent shift in TP signaling to cAMP generation, may limit the negative impact of enhanced TP expression. Other factors that may regulate the dimerization process, such as association with G proteins or chaperone proteins, are a focus of our current research.
We noted a distinct difference between the process of IP homodimerization compared with IPTP heterodimerization. Although IPrLuc:IPYFP BRET was reduced by an excess of unfused IP, neither unfused IP nor TP␣ modified the IPrLuc: TP␣YFP signal. The trivial explanation, that the unfused receptors simply did not interact with the IPrLuc:TP␣YFP heterodimer, seems unlikely. Both BRET saturation ( Figure  2 ) and coimmunoprecipitation 6 experiments clearly demonstrate IP-TP interaction. It is possible that the presence of rLuc and/or YFP sterically prevented competitor access to the site of heterodimer interaction. However, our competition studies with IPrLuc:IPYFP homodimers, together with reports using similarly labeled GPCRs, 26 argue against such blockade. It is more likely, therefore, that within the IPTP␣ heterodimer, the site(s) for IP and TP␣ homodimerization remain accessible, leaving the IPrLuc-TP␣YFP BRET signal unchanged by excess unfused receptors. Multiple dimerization motifs 18, 19 are present in the IP and TP, making it possible that distinct interactions direct their homo-and heterodimerization. Indeed, our data are consistent with oligomerization, a phenomenon reported for several class A GPCRs, 18, 27, 28 in which the IPTP␣ heterodimer can bind additional IP and/or TP␣ molecules. The design of the current BRET studies does not discriminate between formation of dimers and oligomers. Currently, we are using a modified BRET technique to investigate IP-TP oligomerization.
Impaired cAMP generation via IP R212C was evident in HEK293 ( Figure 5A ) and COS-7 11 cells. Platelets from IP R212C heterozygote individuals displayed an exaggerated loss of PGI 2 responsiveness 11 that exceeded the relative impairment observed in IPϩ/Ϫ heterozygous mice, 13 consistent with a dominant negative action of the variant. We established IP R212C dimerization with the wild-type IP and observed a dominant impact of the mutant on wild-type IP cellular distribution and function. We believe that, through formation of the IP:IP R212C dimer, loss of PGI 2 responsiveness is augmented beyond the IP R212C 's discrete signaling deficiency. In addition, coexpression of the TP with IP R212C markedly modified TP signaling, compared with TPϩwildtype IP cotransfectants, such that "normal" TP signaling was restored. Thus, along with the depression of wild-type IP function, IP R212C fails to allow generation of a TP-dependent cAMP signal. Instead, InsP generation approached the level recorded in cells expressing the TP alone. Thus, the overall outcome in IP R212C -expressing cells, stimulated with either IP or TP agonists, was less cAMP and more InsP. In functional terms, this would facilitate deleterious cardiovascular events contributing to the accelerated CVD observed in IP R212C carriers. 11 It is unclear how IP R212C affected signaling changes in its dimeric partners. IP R212C , which is itself concentrated in the ER ( Figure 4C) 11 , promoted retention of the wild-type receptor to the ER. This is consistent with IP homodimerization early in biogenesis and suggests that signaling changes reflect reduced surface receptor expression. In native cells, it is difficult, and misleading, to express sufficiently high levels of IP R212C to impact the wild-type receptor. Thus, we have not confirmed IP R212C -dependent changes in localization of the endogenous IP. It is also possible that the presence of IP R212C interferes with G protein-coupling of the partner receptor directly modifying the signal. Indeed, GPCRs are proposed to function as a pentameric complex containing a receptor dimer and 1 heterotrimeric G protein. 29, 30 Recent elegant investigations of the dopamine D2 receptor demonstrated allosteric modulation of one receptor by the other and transmission of an altered conformation across the dimer interface. Thus, the intrinsic changes associated with the IP R212C mutation may be transmitted to its dimeric partners modifying the signaling outcome. Given that cAMP generation via both IP and TP was offset by IP R212C , we speculate that a modified IP R212C -Gs interaction controls the signaling outcome of the dimeric complex. In keeping with this model, when complexed to the IP R212C , the TP can signal through a Gq-InsP pathway, perhaps because TP-Gq coupling is now permitted.
Numerous studies support the critical antithrombotic and cardiovascular protective role of PGI 2 as a natural restraint on vasoactive mediators, including TxA 2 . 2, 4 Our data suggests that dimerization of the IP and the TP is an integral part of this system. Our studies support the concept that considering the IP and TP as discrete signaling entities is an oversimplification of biological reality. Full understanding of these pathways will require definition of the cell-and contextspecific parameters that direct homo-and heterodimerization in native cells. Importantly, however, our study provides the first evidence for allosteric influence of genetic receptor variants on the function of other receptors, providing a mechanistic basis for dominant effects through dimerization.
